{"id":66204,"date":"2026-05-25T21:18:35","date_gmt":"2026-05-25T13:18:35","guid":{"rendered":"https:\/\/flcube.com\/?p=66204"},"modified":"2026-05-25T21:18:37","modified_gmt":"2026-05-25T13:18:37","slug":"biogen-denali-terminate-parkinsons-drug-biib122-after-phase-iib-luma-study-failure","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66204","title":{"rendered":"Biogen, Denali Terminate Parkinson&#8217;s Drug BIIB122 After Phase IIb LUMA Study Failure"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Biogen Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIIB:NASDAQ\">NASDAQ: BIIB<\/a>)<\/strong> and <strong>Denali Therapeutics Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/DNLI:NASDAQ\">NASDAQ: DNLI<\/a>)<\/strong> jointly announced the termination of development for <strong>BIIB122 (DNL151)<\/strong>, a leucine-rich repeat kinase 2 (<strong>LRRK2<\/strong>) inhibitor, as a treatment for <strong>idiopathic Parkinson&#8217;s disease (PD)<\/strong> following negative results from the Phase IIb <strong>LUMA study<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-status\" class=\"wp-block-heading\">Clinical Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Candidate<\/strong><\/td><td>BIIB122 (DNL151)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>LRRK2 inhibitor<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Idiopathic Parkinson&#8217;s disease<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase IIb (LUMA study)<\/td><\/tr><tr><td><strong>Outcome<\/strong><\/td><td>Failed to slow disease progression<\/td><\/tr><tr><td><strong>Current Status<\/strong><\/td><td>Development terminated for idiopathic PD<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-scientific-rationale-amp-mechanism-of-action\" class=\"wp-block-heading\">Scientific Rationale &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> Leucine-rich repeat kinase 2 (<strong>LRRK2<\/strong>), a regulator of lysosomal function<\/li>\n\n\n\n<li><strong>Hypothesis:<\/strong> Abnormal LRRK2 function in Parkinson&#8217;s disease may lead to neurodegeneration<\/li>\n\n\n\n<li><strong>Therapeutic Approach:<\/strong> Inhibiting LRRK2 activity may restore lysosomal function<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Initially targeted both Parkinson&#8217;s patients with and without LRRK2 gene mutations<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-partnership-amp-financial-context\" class=\"wp-block-heading\">Partnership &amp; Financial Context<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">In August 2020, Biogen acquired exclusive development and commercialization rights to BIIB122 for upwards of <strong>USD 2 billion<\/strong> covering the United States and China markets. The substantial investment reflected high confidence in the drug&#8217;s potential to address a significant unmet medical need in Parkinson&#8217;s treatment.<\/p>\n\n\n\n<h2 id=\"h-revised-development-strategy\" class=\"wp-block-heading\">Revised Development Strategy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Following the setback in the broader Parkinson&#8217;s population, <strong>Denali Therapeutics will independently continue<\/strong> the Phase IIa <strong>BEACON study<\/strong>, which specifically evaluates the efficacy of this small-molecule inhibitor in patients carrying <strong>pathogenic LRRK2 variants<\/strong>. This more targeted approach maintains focus on the genetically defined subpopulation where the biological rationale remains strongest.<\/p>\n\n\n\n<h2 id=\"h-market-implications\" class=\"wp-block-heading\">Market Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The termination represents another challenge in the difficult landscape of neurodegenerative drug development. Despite decades of research, effective disease-modifying therapies for Parkinson&#8217;s remain elusive, with most current treatments addressing only symptomatic relief rather than underlying disease progression.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Investors will be monitoring closely as Denali reports results from the BEACON study, which could determine whether LRRK2 inhibition retains any commercial viability in the Parkinson&#8217;s therapeutic market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial expectations. Actual results may differ materially due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biogen Inc. (NASDAQ: BIIB) and Denali Therapeutics Inc. (NASDAQ: DNLI) jointly announced the termination of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[351,17,1522,993,1521],"class_list":["post-66204","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-biogen","tag-clinical-trial-results","tag-denali-therapeutics","tag-nasdaq-biib","tag-nasdaq-dnli"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biogen, Denali Terminate Parkinson&#039;s Drug BIIB122 After Phase IIb LUMA Study Failure - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Biogen Inc. (NASDAQ: BIIB) and Denali Therapeutics Inc. (NASDAQ: DNLI) jointly announced the termination of development for BIIB122 (DNL151), a leucine-rich repeat kinase 2 (LRRK2) inhibitor, as a treatment for idiopathic Parkinson&#039;s disease (PD) following negative results from the Phase IIb LUMA study.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66204\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen, Denali Terminate Parkinson&#039;s Drug BIIB122 After Phase IIb LUMA Study Failure\" \/>\n<meta property=\"og:description\" content=\"Biogen Inc. (NASDAQ: BIIB) and Denali Therapeutics Inc. (NASDAQ: DNLI) jointly announced the termination of development for BIIB122 (DNL151), a leucine-rich repeat kinase 2 (LRRK2) inhibitor, as a treatment for idiopathic Parkinson&#039;s disease (PD) following negative results from the Phase IIb LUMA study.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66204\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-25T13:18:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-25T13:18:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66204#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66204\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biogen, Denali Terminate Parkinson&#8217;s Drug BIIB122 After Phase IIb LUMA Study Failure\",\"datePublished\":\"2026-05-25T13:18:35+00:00\",\"dateModified\":\"2026-05-25T13:18:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66204\"},\"wordCount\":351,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biogen\",\"Clinical trial results\",\"Denali Therapeutics\",\"NASDAQ: BIIB\",\"NASDAQ: DNLI\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66204#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66204\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66204\",\"name\":\"Biogen, Denali Terminate Parkinson's Drug BIIB122 After Phase IIb LUMA Study Failure - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-25T13:18:35+00:00\",\"dateModified\":\"2026-05-25T13:18:37+00:00\",\"description\":\"Biogen Inc. (NASDAQ: BIIB) and Denali Therapeutics Inc. (NASDAQ: DNLI) jointly announced the termination of development for BIIB122 (DNL151), a leucine-rich repeat kinase 2 (LRRK2) inhibitor, as a treatment for idiopathic Parkinson's disease (PD) following negative results from the Phase IIb LUMA study.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66204#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66204\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66204#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen, Denali Terminate Parkinson&#8217;s Drug BIIB122 After Phase IIb LUMA Study Failure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biogen, Denali Terminate Parkinson's Drug BIIB122 After Phase IIb LUMA Study Failure - Insight, China&#039;s Pharmaceutical Industry","description":"Biogen Inc. (NASDAQ: BIIB) and Denali Therapeutics Inc. (NASDAQ: DNLI) jointly announced the termination of development for BIIB122 (DNL151), a leucine-rich repeat kinase 2 (LRRK2) inhibitor, as a treatment for idiopathic Parkinson's disease (PD) following negative results from the Phase IIb LUMA study.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66204","og_locale":"en_US","og_type":"article","og_title":"Biogen, Denali Terminate Parkinson's Drug BIIB122 After Phase IIb LUMA Study Failure","og_description":"Biogen Inc. (NASDAQ: BIIB) and Denali Therapeutics Inc. (NASDAQ: DNLI) jointly announced the termination of development for BIIB122 (DNL151), a leucine-rich repeat kinase 2 (LRRK2) inhibitor, as a treatment for idiopathic Parkinson's disease (PD) following negative results from the Phase IIb LUMA study.","og_url":"https:\/\/flcube.com\/?p=66204","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-25T13:18:35+00:00","article_modified_time":"2026-05-25T13:18:37+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66204#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66204"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biogen, Denali Terminate Parkinson&#8217;s Drug BIIB122 After Phase IIb LUMA Study Failure","datePublished":"2026-05-25T13:18:35+00:00","dateModified":"2026-05-25T13:18:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66204"},"wordCount":351,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biogen","Clinical trial results","Denali Therapeutics","NASDAQ: BIIB","NASDAQ: DNLI"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66204#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66204","url":"https:\/\/flcube.com\/?p=66204","name":"Biogen, Denali Terminate Parkinson's Drug BIIB122 After Phase IIb LUMA Study Failure - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-25T13:18:35+00:00","dateModified":"2026-05-25T13:18:37+00:00","description":"Biogen Inc. (NASDAQ: BIIB) and Denali Therapeutics Inc. (NASDAQ: DNLI) jointly announced the termination of development for BIIB122 (DNL151), a leucine-rich repeat kinase 2 (LRRK2) inhibitor, as a treatment for idiopathic Parkinson's disease (PD) following negative results from the Phase IIb LUMA study.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66204#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66204"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66204#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biogen, Denali Terminate Parkinson&#8217;s Drug BIIB122 After Phase IIb LUMA Study Failure"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66204","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66204"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66204\/revisions"}],"predecessor-version":[{"id":66205,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66204\/revisions\/66205"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66204"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66204"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}